The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Common misconceptions around MRD for MM prognosis
Measurable residual disease (MRD) is used as a prognostic indictor in a variety of hematological maliganancies, including multiple myeloma (MM). We asked Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, about common misconceptions amongst clinicians when it comes to using MRD as a prognostic marker for MM at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Paiva discusses why patients are often misclassified as MRD-negative, as well as why MRD status should be treated as a simple biomarker that is complemented by other information.
